Are You Positive? –TEST Page

  • You must log in to register
    • Nonmember - $350
    • Full Member - $225
    • Associate Member - $225
    • Emeritus Member - $225
    • Government Associate Member - $225
    • Government Full Member - $225
    • Postdoctoral Researcher/Transitional Member - $125
    • Student Member - $125

This eLearning seminar focuses on genetic toxicology, with an emphasis on navigating challenges associated with positive assay results. Each module covers a core component of the genetic toxicology battery—including in silico assessments, Ames, in vitro micronucleus, and in vivo genetic toxicology assays such as comet and in vivo micronucleus—and addresses relevant guidance, assay design, and their application in drug development. The series goes beyond the fundamentals to explore advanced topics such as historical control data, assay-specific data analysis best practices, and study design factors that influence result interpretation. Case studies illustrate strategies for managing positive findings, including follow-up study options and regulatory considerations. Overall, the series aims to provide participants with practical tools and real-world examples to support informed decision making in genetic toxicology.

These modules feature presentations by recognized experts in the field. Modules are available for purchase as a set. Once the live module presentations conclude, registrants will have on-demand access to the modules for 30 days from the time each archive is first accessed. Each module is approximately 90 minutes.

Disclaimer:
This seminar reflects the views of the speaker and should not be construed to represent the views or policies of the American College of Toxicology. Examples presented in this seminar may have required unique strategies that do not necessarily apply to other modalities or situations. Regulatory guidelines and best practices are constantly evolving, and the viewer is encouraged to independently confirm their understanding with what was presented in this seminar.

  • Contains 3 Component(s) Recorded On: 02/24/2027

    Genetic Toxicology Series

    image
    image


    This module introduces the use of in silico screening tools, including QSAR-based models, with the main focus on supporting risk assessment and decision-making. The session provides background on commonly used in silico assays, their regulatory context, and when these tools are most appropriately implemented across discovery and development. Emphasis is placed on understanding the drivers of positive results, including structural alerts, assay limitations, and model applicability domains. The module additionally discusses the evaluation of nitrosamines, including differences between guideline-based and literature-derived acceptable intake limits, the use of compound-specific cutoffs, and the integration of indication, dosing level, and dosing duration into a holistic risk assessment. Additional topics include the identification and evaluation of impurities, the use of expert-rule and statistical models to support regulatory justification, the importance of training datasets, and factors influencing model selection at different development stages. Case studies are used to illustrate interpretation of outcomes and next steps, including establishing acceptable levels, revisiting chemistry and SAR, or determining when additional testing is warranted. Additional considerations to read-across and analog reasoning for known compounds, TTC framework, and context of human relevance are discussed. 

    Joel Bercu, PhD, MPH, DABT

    Joel Bercu, PhD, MPH, DABT

    Executive Director in the Nonclinical Safety and Pathobiology Group

    Gilead Sciences, Inc.

    Dr. Joel Bercu is an Executive Director in the Nonclinical Safety and Pathobiology group at Gilead Sciences and has over 25 years of public health and toxicology experience in pharmaceuticals. His mission while at these positions is to protect the safety of staff, patients, and the environment. He leads the Environmental and Occupational Toxicology (EOT) group at Gilead. Part of the remit of the EOT group is pharmaceutical safety impurity assessments (including mutagenic / carcinogenic impurities), QSAR assessments of impurities for ICH M7 compliance, and the safety evaluation of potential nitrosamine impurities. Prior to joining Gilead Sciences, he worked at Eli Lilly and Amgen. He is a member of the Society of Toxicology and the Risk Assessment, Occupational and Public Health (where he served as President and Endowment Steward), Computational Toxicology and Medical Devices Specialty Sections, and the American College of Toxicology (ACT). He is currently on the ICH M7 Nitrosamine Addendum Expert Working Group (EWG) and leads several external committees such as chairing the IQ/DruSafe Impurities Working Group and leading the Nitrosamine Research Program at the Health and Environmental Sciences Institute (HESI). He received his BS from Texas A&M University, MPH from the University of Texas – Houston School of Public Health, PhD from Indiana University, and is a Diplomate of the American Board of Toxicology (DABT).

  • Contains 3 Component(s) Recorded On: 03/25/2027

    Genetic Toxicology Series

    image
    image


    This presentation provides a comprehensive review of the bacterial reverse mutation (Ames) assay and emerging new approach methodologies (NAMs) for mutagenicity testing from foundational principles to regulatory strategy. Topics covered include relevant regulatory guidances, appropriate timing of Ames testing across the drug development continuum, considerations for mutagenic impurity control, assay design elements, S9 metabolic activation, and protocol modifications required for enhanced Ames assessment of nitrosamine impurities. Participants will gain a systematic framework for investigating a positive result, encompassing data review, tester strain response pattern interpretation, threshold criteria for a positive call, mechanism-of-action analysis, and selection of appropriate follow-on assays. Risk characterization strategies, including impurity classification and acceptable intake derivation, are also discussed. Case studies illustrate how positive results can be fully investigated and mitigated, and the session concludes with practical guidance on integrating genotoxicity findings into a regulatory pathway, communicating them effectively in regulatory submissions, and an overview of emerging NAMs, including error-corrected sequencing, as evolving complements to the traditional Ames battery within a broader NAM framework.

    Sheroy Minocherhomji, PhD, ERT, FRSB

    Sheroy Minocherhomji, PhD, ERT, FRSB

    Senior Director of Toxicology and Pathology

    Eli Lilly and Company

    Dr. Sheroy Minocherhomji is a translational safety and drug development leader whose career spans the interface of drug development, investigative and regulatory toxicology, genetic toxicology, carcinogenesis and DNA repair mechanisms. As Senior Director of Toxicology and Pathology at Eli Lilly and Company, he holds a dual role, leading the Genetic Toxicology strategy for the portfolio and, as Toxicologist oversees nonclinical safety assessment across all phases of drug development for multiple therapeutic modalities.

    With over a decade of industry experience, he has advanced and led the nonclinical safety of several multimodality therapeutics through clinical development, including bioconjugated oligonucleotides complex biologics and synthetics.

    He is recognized for advancing the science of genotoxicity and carcinogenicity evaluation and for pioneering innovative approaches to genotoxicity risk assessment of xenobiotics. Previously, at Amgen, he established and led the Genome Instability Lab and the Genetic Toxicology Unit, where he was instrumental in the development of next-generation sequencing-based tools — including the Drug-induced Genome Instability Test (DiGIT) and Error Corrected Sequencing (ECS) — that have helped reshape testing paradigms across the genetic toxicology field.

    His scientific foundations were built in academia. A Marie Curie Fellow, he earned his PhD in Health and Medical Sciences from the University of Copenhagen, focusing on epigenetic and genetic mechanisms regulating human disease-associated genes, and subsequently held appointments there as a Danish Medical Council Postdoctoral Fellow, Senior Postdoctoral Fellow, and Assistant Professor in the laboratory of Prof. Ian D. Hickson FRS, where his research focused on DNA repair mechanisms associated with replication stress. His key academic work produced seminal discoveries in synthetic lethality and genome stability, including his discovery of the novel Mitotic DNA Synthesis (MiDAS) pathway, published as first-author papers in Nature and Molecular Cell. He has over 25 peer-reviewed papers and more than 2,300 citations to date with publications in high-impact journals including Nature, Mol Cell, Nat Cell Biol, Nat Cancer, PNAS, Nature Reviews Drug Disc, EMM, RTP, ACS, and IJT.

    He holds an MSc in Human Molecular Genetics from Imperial College London. He is a European Registered Toxicologist (ERT) and was elected Fellow of the Royal Society of Biology (FRSB) in 2025. He has previously been recognized with the Emerging Scientist Award from both the Genetic Toxicology Association (GTA) and the Environmental Mutagenesis and Genomics Society (EMGS). He is active within the GTA, EMGS, ACT, and SOT societies and has spoken globally at cross-industry conferences. He previously served as Chair/President of the GTA and currently serves as a HESI-GTTC Steering Committee Member and Co-Chair of several Working Groups, Co-Chair of the IQ/DruSafe TALG Metabolite Mutagenicity Discussion Group, and a member of ACT's Webinar Committee.

  • Contains 3 Component(s) Recorded On: 04/22/2027

    Genetic Toxicology Series

    image
    image


    This presentation provides an overview of the steps to take when navigating a positive or equivocal in vitro micronucleus test result, including how to utilize relevant regulatory guidance to guide data interpretation and follow-up strategies. The presentation covers how to assess the biological relevance of a positive result and evaluate potential nongenotoxic contributing factors. Methodological approaches to determine the mechanism of action are discussed, including approaches to distinguish between clastogens and aneugens, as well as how to determine potential nonlinear safety thresholds. A real-world case study is shared to illustrate how to address conflicting in vitro and in vivo results within a regulatory submission and strategic decision making to get a program back on track.

    Sucheta Mukherjee, PhD, DABT

    Sucheta Mukherjee, PhD, DABT

    Principal Scientist - Toxicologist

    Genentech, Inc.

    Dr. Sucheta Mukherjee is a board-certified Principal Scientist - Toxicologist at Genentech, Inc., where she designs and oversees nonclinical toxicology programs for small molecule, large molecule, and oligonucleotide discovery and development in oncology, neuroscience, immunology, and ophthalmology indications. She previously worked at Aligos Therapeutics, Inc. (2019–2023) as a project toxicologist for small molecule and oligonucleotide programs focused on liver diseases. She received her doctorate in Pharmacology/Toxicology from the University of California, Davis in 2015 and was a DoD Horizon Award postdoctoral fellow at the University of California, San Francisco from 2016–2019. Dr. Mukherjee has been a member of ACT since 2020, where she served on the Early Career Professionals Subcommittee (ECPSC) from 2020–2023 and is currently serving as an elected member of the Education Committee (EdCom; 2025–present). Within ACT, she co-chaired one annual meeting session in 2021, co-hosted two ECP webinars on IND submissions (2021) and communication for toxicologists (2022), and was a panelist in a 2023 leadership webinar. In 2023, she co-led a mentorship focus group as part of the existing ACT mentorship platform on InterACT as well as outreach initiatives for member and non-member ECPs. As a part of EdCom, she contributes to the planning and implementation of all ACT educational opportunities including the Continuing Education (CE) program for the Annual Meeting, classroom-based courses, online courses, webinars, and podcasts. She is also actively involved in the Northern California Regional Chapter of SOT. She served as Treasurer from 2021–2023 and currently serves as Past President (as a part of the presidential chain; 2023–present), providing guidance to the NorCal SOT Board of Directors as they plan symposia and career development opportunities for the membership, which encompasses toxicologists from academia, CROs, industry, and government. Dr. Mukherjee is also an active member of the IQ DruSafe RNA Therapeutics Working Group curating surveys, presentations and publications for nonclinical strategies for oligonucleotide drug development. Dr. Mukherjee has co-authored nine publications and presented her work at ACT and SOT as well as several other national conferences, but her interest in genetic toxicology stems all the way back to her undergraduate research days studying mechanisms of DNA damage response.

  • Contains 3 Component(s) Recorded On: 05/27/2027

    Genetic Toxicology Series

    image
    image


    This presentation focuses on the role of in vivo genetic toxicology assays within the nonclinical safety assessment of pharmaceuticals, with emphasis on in vivo micronucleus and in vivo comet assays. These assays are critical tools for evaluating clastogenic, aneugenic, and DNA‑damaging potential in the context of whole‑animal exposure and metabolism. The session reviews the scientific rationale, strengths, and limitations of each assay and discusses how positive findings are interpreted within a weight‑of‑evidence framework. Key topics include the ramifications of a positive in vivo result, strategies for confirmatory or follow‑up testing, and factors influencing assay selection, study design, and tissue targeting. Regulatory expectations and implications under relevant global guidance are addressed, including how in vivo data can impact development timelines, risk assessment, and regulatory decision making. The presentation concludes with a case study illustrating a practical approach to navigating a positive in vivo genetic toxicology finding, highlighting data integration, mechanistic considerations, communication with regulators, and potential paths forward. Participants will gain practical insights into applying these assays to support informed, science‑based decision making in drug development.

    Wen Sun, PhD

    Wen Sun, PhD

    Director of Genetic Toxicology

    Pfizer Inc.

    Dr. Wen Sun is the director of the Genetic Toxicology department at Pfizer. She received her PhD in Molecular and Cellular Biology from the University of Iowa and worked as a postdoctoral researcher in the Pharmacology Department at Yale University prior to joining Pfizer seven years ago. Currently, Dr. Sun oversees all scientific and strategic development of genetox at Pfizer, provides subject-matter expertise, and guides teams and chemists away from genotoxicity liabilities. Dr. Sun leads numerous working groups within the Health and Environmental Sciences Institute, focusing on the use of NAM-based approaches in hazard ID and risk management. Dr. Sun has been a long-time member of GTA and currently serves on the board of directors of the Environmental Mutagenesis and Genomics Society.

Registration Fees:

Seminar registration is restricted to single person use only. Please note that all eLearning sales are final. Fees are assessed according to membership status at the time of purchase. No cancellations or refunds will be allotted after payment is processed.

Registration Type Set/Module 1–4
ACT Member $225
ACT Student/Transitional/Postdoctoral Researcher Member $125
Nonmember $350

The Are You Positive? Navigating Genetic Toxicology Challenges eLearning seminar content will only be available until December 31, 2029.